{"id":9331,"date":"2020-05-11T17:33:16","date_gmt":"2020-05-11T12:03:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9331"},"modified":"2023-12-06T11:55:32","modified_gmt":"2023-12-06T06:25:32","slug":"huntingtons-disease-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market","title":{"rendered":"Is the cure for Huntington\u2019s disease on the horizon?"},"content":{"rendered":"\n

Several promising new developments and novel treatment approaches are fuelling Huntington\u2019s disease Market. <\/em><\/p>\n\n\n\n

Progressive neurological disorders such as Parkinson disease (PD), motor neuron disease (MND), Huntington disease (HD), or multiple sclerosis (MS), despite the advent of technological advances in healthcare and medical sciences, poses a huge burden worldwide, which is set to increase in coming decades.
The global need of resources for managing neurological diseases has remained unmet for so long that the absolute number of people, dying or living with disability due to neurological disorders, have increased substantially in the last three decades. Several times, due to associated psychological issues with the brain-related diseases tend to result in attempting suicides by the patients such as in Huntington\u2019s disease. Risk of suicide in Huntington\u2019s disease remains highest, which is also one of the reasons for premature deaths in Huntington\u2019s disease. <\/p>\n\n\n\n

Huntington disease<\/strong> (HD) is an autosomal-dominant neurodegenerative disease characterized by cognitive disturbance, motor abnormalities, and psychiatric symptoms. It is an orphan disease that is inherited genetically and results in a progressive breakdown of the nerve cells. The disease impacts the person\u2019s ability to move, think affecting the person psychologically. <\/p>\n\n\n\n

The disease is a result in mutation in the HTT<\/strong>\ngene responsible for encoding for huntingtin protein whose excess build-up is\nconsidered to be a marker while diagnosing the disease. Moreover, as per the recent\nresearch in the field it was discovered that the number of CAG repeats in the huntingtin\nprotein are also associated with prognosis of the disease. <\/p>\n\n\n\n

Huntington disease degrades the life-quality of an estimated 3 to 7 per 100,000 people<\/strong> of European ancestry as per NIH. The numbers in the US range from 4.1-8.4 per 100,000<\/strong> people estimated a study by S.E.Folstein et al. However, several studies agreed upon a relatively lower preponderance of Huntington\u2019s disease in populations of Japanese, Chinese, and African descent. <\/p>\n\n\n\n

As per a study by Swierzewski et al. titled \u201cHuntington\u2019s Disease Overview, Incidence and Prevalence of HD,\u201d 1 in every 10,000 persons <\/strong>(that accounts for nearly 30,00 people) in the United States are living with Huntington’s disease. Moreover, Juvenile Huntington’s disease occurs in approximately 16% of all the cases. According to another study conducted by Wexler et al. titled \u201cIncidence of adult Huntington’s disease in the UK: a UK-based primary care study and a systematic review,\u201d the Huntington\u2019s disease prevalence<\/a>, as diagnosed and recorded in primary care records, has increased from 5.4 per 100,000 in 1990 to 12.3 per 100,000 in 2010<\/strong> explaining that the occurrence of the disease has increased two-fold in these years.<\/p>\n\n\n\n

The rise in the prevalence of Huntington\u2019s disease forms the major driving forces behind the advancing Huntington\u2019s disease market, says DelveInsight. <\/strong><\/p>\n\n\n

\n
\"Huntington\u2019s
Huntington\u2019s disease Market<\/a><\/strong><\/figcaption><\/figure><\/div>\n\n\n

Huntington\u2019s disease Market<\/strong> and Unmet needs<\/h2>\n\n\n\n

At present, Huntington\u2019s disease market<\/a><\/strong> has no effective treatment that can halt or delay the progression of the disease. Till date, Huntington\u2019s disease remains incurable. No treatments available can alter the course of the disease, however, medications can lessen some symptoms of movement and psychiatric disorders. Only FDA-approved drug involved to treat chorea associated with Huntington\u2019s disease, which is the most notable known symptom, is Tetrabenazine<\/strong> (Xenazine), which is again a symptomatic approach to manage the disease. Other medications that are symptomatic in nature include antipsychotic drugs such as haloperidol<\/strong> (Haldol) and chlorpromazine<\/strong>, and other medications such as amantadine<\/strong>, levetiracetam<\/strong> (Keppra), and clonazepam<\/strong> (Klonopin) that help to alleviate the symptoms. <\/p>\n\n\n\n

Moreover, to target the psychiatric symptoms medications such as antidepressants including citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), and sertraline (Zoloft); antipsychotic drugs including quetiapine (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) followed by mood-stabilizing drugs namely valproate (Depacon), carbamazepine (Carbatrol, Epitol, Tegretol) and lamotrigine (Lamictal) are also prescribed to Huntington\u2019s disease patients. <\/p>\n\n\n\n

However, several promising new developments and novel treatment approaches prove to be potential in improving the lives of Huntington\u2019s disease patients, reducing the risk of hereditary transfer and fuelling Huntington\u2019s disease Market. <\/p>\n\n\n\n

RG6042<\/strong> by Roche, Neflamapimod<\/strong>\nunder development by Vertex and EIP pharma, Pepinemab<\/strong> of Vaccinex, SOM3355<\/strong>\nof OM Biotech SL and ALZ002<\/strong> of Allianz Pharma are some of the emerging\npipeline products<\/a> in the Huntington\u2019s disease market. Several companies such as Hoffmann-La Roche<\/strong>\n(RG6042), EIP Pharma<\/strong> (Neflamapimod), Vaccinex<\/strong> (Pepinemab), and SOM\nBiotech SL<\/strong> (SOM3355) and others are in the process of developing multiple-stage\nproducts that have the potential to create a significant positive shift in the Huntington\u2019s\ndisease market Size.<\/p>\n\n\n\n

With trials testing immunotherapies to target the mutation, using antisense oligonucleotides (ASOs), and other drugs that are approved or thought to have had the potential to treat other diseases, the Huntington\u2019s disease market scenario looks quite optimistic enough to the point that soon enough Huntington\u2019s disease would be manageable and have standard treatment options. <\/p>\n","protected":false},"excerpt":{"rendered":"

Several promising new developments and novel treatment approaches are fuelling Huntington\u2019s disease Market. Progressive neurological disorders such as Parkinson disease (PD), motor neuron disease (MND), Huntington disease (HD), or multiple sclerosis (MS), despite the advent of technological advances in healthcare and medical sciences, poses a huge burden worldwide, which is set to increase in coming […]<\/p>\n","protected":false},"author":1,"featured_media":9335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[1638,18312,18313,18314,18315,18304,18305,1639,18309,18307,524,18310,18311,18308],"industry":[17225],"therapeutic_areas":[17238,17245,17234],"class_list":["post-9331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-eip-pharma","tag-huntingtonas-disease","tag-huntingtonas-disease-market","tag-huntingtonas-disease-pipeline","tag-huntingtonas-disease-treatment","tag-huntingtons-disease","tag-huntingtons-disease-prevalence","tag-neflamapimod","tag-pepinemab","tag-rg6042","tag-roche","tag-som-biotech-sl","tag-som3355","tag-vaccinex","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nHuntington's Disease Market | HD Market | DelveInsight<\/title>\n<meta name=\"description\" content=\"With trials testing immunotherapies, antisense oligonucleotides, and other drugs in the pipeline for HD treatment, Huntington\u2019s disease market scenario...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huntington's Disease Market | HD Market | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"With trials testing immunotherapies, antisense oligonucleotides, and other drugs in the pipeline for HD treatment, Huntington\u2019s disease market scenario...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-11T12:03:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-06T06:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huntington's Disease Market | HD Market | DelveInsight","description":"With trials testing immunotherapies, antisense oligonucleotides, and other drugs in the pipeline for HD treatment, Huntington\u2019s disease market scenario...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market","og_locale":"en_US","og_type":"article","og_title":"Huntington's Disease Market | HD Market | DelveInsight","og_description":"With trials testing immunotherapies, antisense oligonucleotides, and other drugs in the pipeline for HD treatment, Huntington\u2019s disease market scenario...","og_url":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-11T12:03:16+00:00","article_modified_time":"2023-12-06T06:25:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market","url":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market","name":"Huntington's Disease Market | HD Market | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease.jpg","datePublished":"2020-05-11T12:03:16+00:00","dateModified":"2023-12-06T06:25:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"With trials testing immunotherapies, antisense oligonucleotides, and other drugs in the pipeline for HD treatment, Huntington\u2019s disease market scenario...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease.jpg","width":772,"height":482,"caption":"Huntington\u2019s disease Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/11172550\/Huntington%E2%80%99s-disease-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">EIP Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Huntington\u0092s Disease Prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">neflamapimod<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pepinemab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">RG6042<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">SOM Biotech SL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">SOM3355<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Vaccinex<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EIP Pharma<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Market<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u00e2\u0080\u0099s disease Treatment<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u0092s Disease Prevalence<\/span>","<span class=\"advgb-post-tax-term\">neflamapimod<\/span>","<span class=\"advgb-post-tax-term\">Pepinemab<\/span>","<span class=\"advgb-post-tax-term\">RG6042<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">SOM Biotech SL<\/span>","<span class=\"advgb-post-tax-term\">SOM3355<\/span>","<span class=\"advgb-post-tax-term\">Vaccinex<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 11, 2020","modified":"Updated on Dec 6, 2023"},"absolute_dates_time":{"created":"Posted on May 11, 2020 5:33 pm","modified":"Updated on Dec 6, 2023 11:55 am"},"featured_img_caption":"Huntington\u2019s disease Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9331"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9335"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9331"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9331"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}